Substantial evidence suggests that chronic hyperuricemia is an independent risk factor for
hypertension, metabolic syndrome, chronic kidney disease (CKD) and cardiovascular …

During the last century, there has been an increasing prevalence of hyperuricaemia noted in
many populations. While uric acid is usually discussed in the context of gout …

The idea that asymmetric dimethylarginine (ADMA) accumulation may be a cardiovascular
risk factor in patients with end-stage renal disease was advanced by Vallance in 1992 …

Drug dosage adjustment for patients with acute or chronic kidney disease is an accepted
standard of practice. The challenge is how to accurately estimate a patient's kidney function …

Background—Increased blood concentrations of the endogenous nitric oxide synthase
(NOS) inhibitor asymmetrical dimethylarginine (ADMA) have been linked to excess …

Objective To evaluate the effect of different treatment strategies on enterohaemorrhagic
Escherichia coli O104: H4 induced haemolytic uraemic syndrome. Design Multicentre …

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelial nitric oxide
(NO) synthase. Its concentration is elevated in patients with end-stage renal disease …

In patients with uremia, increased blood concentrations of the endogenous nitric oxide
synthase inhibitor asymmetric dimethylarginine (ADMA) have been linked to the severity of …

The relationship among insulin resistance, adiponectin, and cardiovascular (CV) morbidity
in patients with mild and moderate kidney disease was investigated. Insulin sensitivity …

Background. Dosing of most drugs must be adapted in renal insufficiency, making accurate
assessment of renal function essential in clinical medicine. Furthermore, even modest …